Cutting to the chase, this struggling biotech has been averaging a quarterly cash burn rate of $21 million over the last year -- and that's before the company took on Afrezza's commercialization, meaning that MannKind probably has less than two quarters remaining in terms of a rock solid cash runway. Now,MannKind does have some additional financing options available to extend its runway, such as its $50 million or so in at-the-market (ATM) stock offerings, as well as a $30 million loan agreement with The Mann Group.